Food Factors with Glucagon-Like Peptide-1 Releasing Activity Improve Glucose Tolerance

Why GLP-1 matters

If you formulate foods for blood sugar control, GLP-1 is where the action is. This gut hormone comes from enteroendocrine L cells and responds to meal ingestion. It helps lower glucose and sends satiety signals. Not every ingredient triggers it. That creates an opening for food formulators.

The paper behind this, published as DOI: 10.3390/ijms22126623, looked at food factors with GLP-1 releasing activity. In particular, it examined two ingredients: D-allulose and resistant maltodextrin (RMD). Both improved glucose tolerance in rodent models, but they did it through different paths.

Background: A hormone worth targeting

GLP-1 is not just a drug target. It is part of the normal digestive response. When L cells sense food, they release GLP-1. The hormone then acts on the pancreas to release insulin, slows gastric emptying, and helps the brain register fullness.

For formulators, the practical question is which ingredients can nudge this system. The study focused on food-derived factors, not pharmaceuticals. That makes the findings directly relevant to product development.

What the study did

The paper examined evidence on D-allulose and resistant maltodextrin. D-allulose is a non-metabolizable sugar. It provides sweetness without being fully used as glucose. RMD is a resistant maltodextrin, a fiber that reaches the gut and ferments.

Both were evaluated in rats and mice. The endpoints were GLP-1 release, GIP release, feeding behavior, and glucose tolerance.

Key findings

D-allulose consistently induced GLP-1 secretion in rats and mice. When given orally to mice, it suppressed overeating and hyperglycemia. That effect came with a notable precision point: GIP secretion did not change.

GIP matters. It is another incretin hormone, but its role in metabolic health is more complicated. An ingredient that raises GLP-1 without touching GIP gives you a targeted way to support glycemic control. GIP stayed flat. That is the kind of specificity formulators should look for.

Resistant maltodextrin worked differently. Continuous feeding increased plasma GLP-1 in normal rats and in rats fed a high-fat/high-sucrose diet. This was accompanied by increased production of short-chain fatty acids. In other words, RMD likely works through fermentation.

Ingredient	GLP-1 effect	GIP effect	Other observed effects
D-allulose	Induced GLP-1 secretion in rats and mice	No change	Oral dosing suppressed overeating and hyperglycemia in mice
Resistant maltodextrin (RMD)	Raised plasma GLP-1 after continuous feeding	No data in these findings	Increased short-chain fatty acids; effective in normal and high-fat/high-sucrose fed rats

What this means for manufacturers

If you work with sugar replacement, D-allulose deserves serious attention. It is a sweetener, but it is also a signaling molecule. The fact that it does not trigger GIP makes it different from many other sweetening options. That difference matters in products aimed at diabetes or weight management.

Resistant maltodextrin gives you a fiber route to the same target. In the RMD studies, continuous feeding raised plasma GLP-1. That points to daily-use formats. Sachets, bars, shakes, and breakfast items all make sense. The rise in short-chain fatty acids is a useful secondary signal, especially for products already positioned as gut-friendly.

Neither ingredient is a magic bullet. But the study points to a clear formulation strategy: combine nutrient-based approaches that activate GLP-1 through distinct mechanisms. D-allulose stimulates GLP-1 release. RMD works through fermentation byproducts. They are not interchangeable, and they do not need to be.

FAQ

Can these findings be used in human products?

The data here come from animal models. Human research is still needed. That said, D-allulose and RMD are both already used in foods. Their compatibility with existing formulations is not the hurdle. The hurdle is label claims, which require human evidence.

Is D-allulose just another sweetener?

No. It induced GLP-1 secretion and suppressed overeating and hyperglycemia in mice. Its inability to change GIP secretion gives it a profile that standard sweeteners do not have. Sweetness is only part of the value.

Should I combine D-allulose and resistant maltodextrin?

Possibly. They appear to act through different mechanisms. D-allulose affects GLP-1 directly. RMD increases short-chain fatty acids alongside GLP-1. Combining them could offer broader glucose control, but formulation testing is needed.

The takeaway is practical: GLP-1 is an accessible target for food, and D-allulose and RMD are two ways to reach it. Pick based on your format, your label, and the metabolic story you want to tell. Then test.